Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001701541-23-000032
Filing Date
2023-05-09
Accepted
2023-05-09 07:45:47
Documents
58
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bdtx-20230331.htm   iXBRL 10-Q 922282
2 EX-31.1 exhibit311_q12023.htm EX-31.1 12589
3 EX-31.2 exhibit312_q12023.htm EX-31.2 12360
4 EX-32.1 exhibit321_q12023.htm EX-32.1 9408
  Complete submission text file 0001701541-23-000032.txt   4505126

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdtx-20230331.xsd EX-101.SCH 29606
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bdtx-20230331_cal.xml EX-101.CAL 50847
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bdtx-20230331_def.xml EX-101.DEF 113143
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdtx-20230331_lab.xml EX-101.LAB 434552
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdtx-20230331_pre.xml EX-101.PRE 268538
52 EXTRACTED XBRL INSTANCE DOCUMENT bdtx-20230331_htm.xml XML 666909
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39200 | Film No.: 23900021
SIC: 2836 Biological Products, (No Diagnostic Substances)